Xeris Biopharma Holdings (XERS) drew fresh investor attention after reporting fourth quarter 2025 earnings per share of US$0.06 on revenue of US$85.8 million, both above prior projections and supported by a reiteration of positive analyst views.

See our latest analysis for Xeris Biopharma Holdings.

At a share price of US$6.05, Xeris Biopharma’s recent 8.04% 7 day share price return and 4.13% 30 day share price return contrast with a 17.69% decline year to date. At the same time, the 37.19% 1 year and very large 3 year total shareholder returns suggest that longer term momentum has been stronger than the shorter term share price pattern implies.

If Xeris’s latest earnings surprise has you looking beyond a single stock, this is a good moment to see which other healthcare names are catching attention through our 37 healthcare AI stocks

With earnings and revenue ahead of expectations and the share price still well below analyst targets, the key question now is whether Xeris Biopharma is trading at a discount or if the market is already pricing in its future growth.

Most Popular Narrative: 45.7% Undervalued

With Xeris Biopharma last closing at $6.05 versus a narrative fair value of $11.14, the widely followed view frames the current price as a steep discount and ties that gap to future cash generation and profitability assumptions.

The impending launch of XP-8121, which utilizes proprietary delivery technology to address a significant unmet need in hypothyroidism, opens the door to a high-value market segment underserved by innovation and may create new revenue streams and long-term margin expansion. Partnered launches, like Gvoke VialDx with American Regent, and ongoing investments in both licensing and differentiated drug delivery technologies, may allow Xeris to participate in industry preferences for innovative, easy-to-administer, and cost-effective therapies and could support future top-line and royalty income growth.

Read the complete narrative.

Want to see what underpins that valuation gap? The narrative focuses on faster revenue expansion, sharply higher margins, and a richer earnings multiple. Curious which specific financial milestones are included in the analysis and how sensitive that $11.14 fair value is to them? The full narrative lays out the framework behind those targets.

Result: Fair Value of $11.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upbeat story hinges on a narrow product lineup and rising R&D and SG&A costs, which could pressure margins if revenue momentum slows.

Find out about the key risks to this Xeris Biopharma Holdings narrative.

Next Steps

If this mix of optimism and concern feels familiar, that is exactly why it is worth looking at the numbers yourself and moving quickly to shape your own view. You can start with the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Xeris has caught your eye, do not stop there. Use the screener to quickly spot other opportunities that might better match your goals and risk comfort.

• Target potential mispricings by scanning a focused set of companies that look cheap on quality metrics through the 62 high quality undervalued stocks.
• Prioritize resilience by zeroing in on businesses highlighted by the 68 resilient stocks with low risk scores and see which names offer lower risk profiles.
• Hunt for early stage potential by checking the 32 elite penny stocks with strong financials where smaller names with room to develop are grouped in one place.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.